Dravet Syndrome clinical trials at UC Irvine

1 in progress, 0 open to eligible people

Showing trials for

  • EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

    Sorry, not currently recruiting here

    This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole HCL (EPX-100) as adjunctive therapy in children and adult participants with Dravet syndrome.

    Orange, California and other locations

Our lead scientists for Dravet Syndrome research studies include .

Last updated: